Protective Gr1low Monocytes and Macrophages in Compensated Cardiac Hypertrophy to Limit Decompensation and Heart Damaging
The PROMOMA trial, sponsored by Assistance Publique - Hôpitaux de Paris, aims to elucidate the protective role of Gr1low monocytes and macrophages in patients with compensated cardiac hypertrophy. Given the increasing prevalence of heart failure and its associated healthcare costs, successful outcomes could lead to novel therapeutic strategies that may significantly impact the heart failure market. The trial's focus on identifying specific biomarkers for compensated cardiac hypertrophy may position the sponsor favorably in the competitive landscape, particularly if these biomarkers can be translated into diagnostic or therapeutic products. The anticipated completion date in April 2024 suggests a timeline for potential data readouts that could inform future development pathways and partnerships.
Indication: Left Ventricular Hypertrophy
Modality: RNA therapy
Target: Cardiac macrophages and their role in the transition from compensated cardiac hypertrophy to heart failure.
Sponsor: Assistance Publique - Hôpitaux de Paris
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Cardiac macrophages and their role in the transition from compensated cardiac hypertrophy to heart failure.
View original source fields
Condition raw: Left Ventricular Hypertrophy
Condition normalized: Left Ventricular Hypertrophy
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: Cardiac macrophages and their role in the transition from compensated cardiac hypertrophy to heart failure.
Target normalized: Cardiac macrophages and their role in the transition from compensated cardiac hypertrophy to heart failure.